Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-1,361
Closed -$29K 8328
2017
Q2
$29K Buy
1,361
+1,136
+505% +$19.5K ﹤0.01% 6042
2017
Q1
$3K Sell
225
-947
-81% -$13.3K ﹤0.01% 7249
2016
Q4
$16K Buy
1,172
+1,058
+928% +$13.4K ﹤0.01% 6665
2016
Q3
$1K Sell
114
-2,001
-95% -$25K ﹤0.01% 7588
2016
Q2
$30K Sell
2,115
-17,209
-89% -$237K ﹤0.01% 5950
2016
Q1
$271K Buy
19,324
+18,846
+3,943% +$256K ﹤0.01% 4277
2015
Q4
$7K Buy
+478
New +$7.13K ﹤0.01% 7561
2015
Q3
Sell
-1,781
Closed -$18K 8872
2015
Q2
$18K Buy
1,781
+301
+20% +$3.16K ﹤0.01% 6996
2015
Q1
$15K Sell
1,480
-858
-37% -$9.69K ﹤0.01% 7311
2014
Q4
$24K Buy
+2,338
New +$24.6K ﹤0.01% 7415

UBS Group's NCIT Position: Q3 2017 in Review

UBS Group sold out of NCI, Inc. (NCIT) in Q3 2017, closing a stake of 1,361 shares — an estimated $29K sold.

UBS Group first reported a position in NCIT in Q4 2014 and held it in 10 quarters. The position peaked at $271K in Q1 2016. 0 funds tracked by Wall St. Rank hold NCIT as of Q3 2017.

  • UBS Group reported no remaining NCI, Inc. position as of Q3 2017 after selling out during the quarter.
  • UBS Group sold 1,361 NCI, Inc. shares in Q3 2017, an estimated $29K.
  • UBS Group first reported a position in NCI, Inc. in Q4 2014 and held it in 10 quarters.
  • UBS Group's NCI, Inc. position peaked at $271K in Q1 2016.
  • 0 funds tracked by Wall St. Rank held NCI, Inc. as of Q3 2017.

Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.